<?xml version="1.0" encoding="UTF-8"?>
<p id="Par33">Given the rationale behind expansion of the oligometastatic paradigm (i.e. with the COMET-10 trial), we believe it is reasonable to postulate that the benefits of stereotactic radiotherapy may be independent of lesion number provided the treatment can be performed without excess radiation related toxicity. In this modified phase I dose escalation trial, we will test the hypothesis that SABR can be safely delivered to all sites of polymetastatic (&gt;â€‰10 lesions) cancer in patients for whom standard of care systemic therapies have been exhausted (or if additional systemic therapy is refused) to determine the maximally tolerated dose (MTD).</p>
